Amphastar Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $152.9M TTM FCF base; 3% annual FCF growth years 1-5; 2% years 6-10; 11.5% discount rate (reflecting generic-competition and litigation risk); 2% terminal growth; $398.2M net debt; 42.54M shares outstanding.

Reasoning: Amphastar is a profitable specialty/generic injectables manufacturer with real free cash flow, supporting a standard DCF, but growth and discount-rate assumptions were set conservatively given ongoing generic-competition and litigation risks common to its product portfolio.